BRIEF published on 04/23/2025 at 09:10, 7 months 12 days ago BioNxt Solutions progresse dans une étude sur le traitement de la sclérose en plaques Sclérose En Plaques Cladribine Solutions BioNxt Étude De Bioéquivalence Innovation En Matière D'administration De Médicaments
PRESS RELEASE published on 04/23/2025 at 09:05, 7 months 12 days ago BioNxt Solutions Prepares for Human Bioequivalence Study For MS BioNxt Solutions Inc. reports advanced preparation for human bioequivalence study of BNT23001, a novel sublingual thin-film Cladribine formulation for Multiple Sclerosis treatment BioNxt Solutions Inc. Multiple Sclerosis Treatment Sublingual Thin-Film BNT23001 Human Bioequivalence Study
BRIEF published on 03/15/2025 at 00:05, 8 months 21 days ago BioNxt Solutions Closes Final Tranche of Convertible Debenture Offering Private Placement Convertible Debenture Warrants Financing BioNxt Solutions
BRIEF published on 03/15/2025 at 00:05, 8 months 21 days ago BioNxt Solutions clôture la dernière tranche de son offre d'obligations convertibles Financement Placement Privé Mandats Obligation Convertible Solutions BioNxt
PRESS RELEASE published on 03/15/2025 at 00:00, 8 months 21 days ago BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement BioNxt Solutions Inc. completes final tranche of convertible debenture Offering for $900,000. Funds to be used for product dev, IP, debt repayment, and working capital Private Placement Convertible Debenture Healthcare BioNxt Solutions Inc. Drug Delivery Technologies
BRIEF published on 03/01/2025 at 01:40, 9 months 4 days ago BioNxt Solutions Secures $1.6 Million in Convertible Debenture Private Placement Private Placement Convertible Debenture Investment BioNxt Solutions Proceeds Utilization
BRIEF published on 03/01/2025 at 01:40, 9 months 4 days ago BioNxt Solutions obtient 1,6 million de dollars en placement privé d'obligations convertibles Investissement Placement Privé Obligation Convertible Solutions BioNxt Utilisation Des Recettes
PRESS RELEASE published on 03/01/2025 at 01:35, 9 months 4 days ago BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement BioNxt Solutions Inc. closes first tranche of convertible debenture units Offering, raising $1.6M. Proceeds for product development, IP filings, debt repayment, and working capital Private Placement BioNxt Solutions Inc. Intellectual Property Product Development Convertible Debenture Units
BRIEF published on 02/24/2025 at 15:05, 9 months 9 days ago BioNxt Solutions Launches Debenture Unit Financing Private Placement Regulatory Approvals Convertible Securities Debenture Units Compensation Warrants
BRIEF published on 02/24/2025 at 15:05, 9 months 9 days ago BioNxt Solutions lance un financement par unité d'obligations Placement Privé Approbations Réglementaires Unités D'obligations Titres Convertibles Mandats D'indemnisation
Published on 12/05/2025 at 21:20, 12 minutes ago Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 32 minutes ago The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 1 hour 7 minutes ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 1 hour 17 minutes ago When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 42 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 18:58, 2 hours 34 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 3 hours 17 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 3 hours 46 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 4 hours 14 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 4 hours 14 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 6 hours 22 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 6 hours 22 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 34 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
